A Study to Learn About Patients With Non-Small Cell Lung Cancer (NSCLC) Who Took Lorlatinib as Their First Treatment

NCT07567352 · clinicaltrials.gov ↗

ACTIVE_NOT_RECRUITING

Status

200

Enrollment

INDUSTRY

Sponsor class

Conditions

Non-Small-Cell Lung
ALK-positive Advanced NSCLC
ALK-positive Non-small-cell Lung Cancer
ALK-positive NSCLC

Interventions

DRUG: lorlatinib

Sponsor

Pfizer